TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinomaResearch in context

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinomaResearch in context

Background: The role of tumor necrosis factor alpha (TNF-α) in targeted therapy for hepatocellular carcinoma (HCC) remains largely unknown. The current study aimed to clarify the mechanistic effects of targeting TNF-α to overcome sorafenib resistance in HCC. Methods: A correlation of TNF-α expressio...

Full description

Bibliographic Details
Main Authors:	Wenliang Tan, Xuan Luo, Wenda Li, Jinyi Zhong, Jun Cao, Sicong Zhu, Xianqing Chen, Rui Zhou, Changzhen Shang, Yajin Chen
Format:	Article
Language:	English
Published:	Elsevier 2019-02-01
Series:	EBioMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396418306248

Similar Items

Corrigendum to “TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma” [EBioMedicine 40 (2019) 446–456]
by: Wenliang Tan, et al.
Published: (2022-06-01)

GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma
by: Wenliang Tan, et al.
Published: (2023-02-01)

High Expression of Long Non-Coding RNA TMCO1-AS1 is Associated With Poor Prognosis of Hepatocellular Carcinoma
by: Xuelian Huang, et al.
Published: (2022-01-01)

Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma
by: Jialiang Luo, et al.
Published: (2022-10-01)

Integrative analysis of h-prune as a potential therapeutic target for hepatocellular carcinomaResearch in context
by: Haotian Liao, et al.
Published: (2019-03-01)

Comprehensive molecular and immunological characterization of hepatocellular carcinomaResearch in context
by: Shu Shimada, et al.
Published: (2019-02-01)

Low expression of long noncoding RNA CTC‐297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma
by: Sicong Zhu, et al.
Published: (2019-12-01)

Development and validation of a CIMP-associated prognostic model for hepatocellular carcinomaResearch in context
by: Ganxun Li, et al.
Published: (2019-09-01)

TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
by: Hui‐Huang Lai, et al.
Published: (2019-04-01)

Prognostic stratification based on HIF-1α signaling for evaluating hypoxia status and immune landscape in hepatocellular carcinoma
by: Hongkai Zhuang, et al.
Published: (2023-05-01)

Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells
by: Chih-Ta Chen, et al.
Published: (2020-03-01)

Tumor microenvironment responsive nano-platform for overcoming sorafenib resistance of hepatocellular carcinoma
by: Wenjing Xu, et al.
Published: (2024-02-01)

A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib
by: Silvia Pietrobono, MD, et al.
Published: (2021-01-01)

Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma
by: Hongkai Zhuang, et al.
Published: (2022-05-01)

Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
by: Ning Zheng, et al.
Published: (2019-05-01)

A FITM1-Related Methylation Signature Predicts the Prognosis of Patients With Non-Viral Hepatocellular Carcinoma
by: Jie Chen, et al.
Published: (2020-02-01)

CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling
by: Zibo Chen, et al.
Published: (2022-04-01)

Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma
by: Hewen Shi, et al.
Published: (2023-05-01)

Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinomaResearch in context
by: Botao Fa, et al.
Published: (2019-06-01)

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinomaResearch in context
by: Junyu Long, et al.
Published: (2019-04-01)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
by: Gong Zhang, et al.
Published: (2022-07-01)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
by: Xiao-Dong Yang, et al.
Published: (2021-01-01)

Ellagic acid inhibits tumor growth and potentiates the therapeutic efficacy of sorafenib in hepatocellular carcinoma
by: Zhenju Tan, et al.
Published: (2024-01-01)

THE REASONS OF RESISTANCE TO THE TNF α INHIBITORS AND WAYS OF ITS OVERCOMING
by: E.I. Alexeeva, et al.
Published: (2009-01-01)

THE REASONS OF RESISTANCE TO THE TNF α INHIBITORS AND WAYS OF ITS OVERCOMING
by: E.I. Alexeeva, et al.
Published: (2009-11-01)

Targeting cancer stem cell signature gene SMOC-2 Overcomes chemoresistance and inhibits cell proliferation of endometrial carcinomaResearch in context
by: Huan Lu, et al.
Published: (2019-02-01)

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death
by: Bisha Ding, et al.
Published: (2021-06-01)

Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinomaResearch in context
by: Yang Cheng, et al.
Published: (2019-02-01)

Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinomaResearch in context
by: Hong Peng, et al.
Published: (2019-08-01)

Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway
by: Feng Qi, et al.
Published: (2021-09-01)

Sorafenib for the treatment of advanced hepatocellular carcinoma
by: M Connock, et al.
Published: (2010-05-01)

Sorafenib for the treatment of advanced hepatocellular carcinoma
by: M Connock, et al.
Published: (2010-05-01)

Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
by: Junji Furuse
Published: (2008-11-01)

Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach
by: Wai Har Ng, et al.
Published: (2024-01-01)

Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Sara M. Atwa, et al.
Published: (2021-08-01)

Sorafenib Resistance Contributed by IL7 and MAL2 in Hepatocellular Carcinoma Can Be Overcome by Autophagy-Inducing Stapled Peptides
by: Jeffrey C. To, et al.
Published: (2023-11-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)

Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinomaResearch in context
by: Jing Wen, et al.
Published: (2022-12-01)

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
by: Sheng-Long Ye, et al.
Published: (2018-03-01)